+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 75Years
All Genders
ID07788118

Exploring Memory-Enhanced 7x19-THEMIS CAR-T Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma Single-Arm Study with Historical Controls

Led by Second Affiliated Hospital, Zhejiang University, School of Medicine · Updated on 2026-08-26

70

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of the 7x19-THEMIS CAR-T cell therapy for patients with relapsed or refractory large B-cell lymphoma, including subtypes such as diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, transformed follicular lymphoma, and mantle cell lymphoma. The study aims to compare the 3-month objective response rate and complete remission rate of this new therapy with historical control data. Participants receive a single intravenous dose of the 7x19-THEMIS CAR-T cells, which are specially designed to target CD19-positive lymphoma cells. The trial is a single-arm study without randomization, focusing on determining the recommended phase II dose and monitoring safety outcomes, including immune-related side effects and blood cell toxicities, over the first month. Longer-term outcomes such as progression-free survival and overall survival are followed for up to 2 to 5 years. During the study, participants undergo multiple assessments including blood tests to monitor immune response and toxicity, as well as imaging to evaluate lymphoma lesions. Researchers also track the presence and activity of CAR-T cells in the body and recovery of B cells at various intervals up to five years. Participants must attend scheduled visits for dosing, laboratory tests, and evaluations, with the primary measurements focused on response rates and safety within the first three months.

CONDITIONS

Brief Title

A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Research Team

W

Wenbin Qian,Professor

W

Wen Lei,Doctor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here